close
MENU
The Grind
7 mins to read

Biotech chemist Iona Weir has a cunning GMP manufacturing plan

Following successful clinical trials, her R&D discovery company is hoping to exit via big pharma.

Brand ambassador Robyn Malcolm and Weir Science founder Iona Weir.

Key points
  • What's at stake: Entrepreneurial scientist Iona Weir hopes she and her backers can exit Weir Science to a big pharma buyer after successful clinical trials on her hero ingredient Myrecil, which treats women who have Genitourinary Syndrome of Menopause (GSM).
  • Background: Weir applied to human cells her scientific know-how on reversing cell death in plants, developing a patented skincare range. She is now seeing FDA approval for its use for GSM. She needs to upgrade to GMP manufacturing to interest pharma buyers.
  • Key players: Iona Weir, Weir Science, FDA, Daniel Barnes, Paul Dallimore, John Kitto.

One of the most famous quotes from the long-running BBC comedy series Blackadder is when Edmund Blackadder’s sidekick Baldrick says: “My Lord, I have a cunning plan.”

So, too, does Kiwi scientist and company CEO Dr Iona Weir. Her company, Weir Science, recently successfully completed a

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual
Group membership
NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Fiona Rotherham Fri, 18 Jul 2025
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Key points
  • What's at stake: Entrepreneurial scientist Iona Weir hopes she and her backers can exit Weir Science to a big pharma buyer after successful clinical trials on her hero ingredient Myrecil, which treats women who have Genitourinary Syndrome of Menopause (GSM).
  • Background: Weir applied to human cells her scientific know-how on reversing cell death in plants, developing a patented skincare range. She is now seeing FDA approval for its use for GSM. She needs to upgrade to GMP manufacturing to interest pharma buyers.
  • Key players: Iona Weir, Weir Science, FDA, Daniel Barnes, Paul Dallimore, John Kitto.
Biotech chemist Iona Weir has a cunning GMP manufacturing plan
The Grind,
110076
true